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Agitation is common in the medical and psychiatric emergency department, and appropriate
management of agitation is a core competency for emergency clinicians. In this article, the authors
review the use of a variety of first-generation antipsychotic drugs, second-generation antipsychotic
drugs, and benzodiazepines for treatment of acute agitation, and propose specific guidelines for
treatment of agitation associated with a variety of conditions, including acute intoxication, psychiatric
illness, delirium, and multiple or idiopathic causes. Pharmacologic treatment of agitation should be
based on an assessment of the most likely cause of the agitation. If agitation results from a delirium or
other medical condition, clinicians should first attempt to treat the underlying cause instead of simply
medicating with antipsychotics or benzodiazepines. [West J Emerg Med. 2012;13(1):26–34.]
INTRODUCTION
The proper management of an agitated patient is essential
to keep staff safe and ensure appropriate treatment for the
patient. Most emergency physicians think of agitation as one of
the simplest cases to treat, with haloperidol being a common
approach in many emergency departments.
1–4 In most
circumstances, nonpharmacologicmethods of behavior control,
such as a verbal intervention, de-escalation, or even nicotine
replacement therapy, may be helpful initially to manage
agitated patients.
5,6 When medications are required, second-
generation antipsychotics, preferred by many psychiatrists over
ﬁrst-generation antipsychotics for long-term management of
psychiatric illnesses, have also become increasingly used in the
acute setting for management of agitation.
7 This paper
represents consensus recommendations from a workgroup of
the American Association for Emergency Psychiatry. This
workgroup convened in 2010–2011 to recommend best
practices in the use of medication to manage agitated patients in
the emergency setting.
8
THE RATIONALE FOR USING MEDICATION
Agitation is prevalent in the emergency setting. The
National Emergency Department Safety Study, for instance,
documented that at least 25% of emergency department staff
felt safe at work ‘‘sometimes,’’ ‘‘rarely,’’ or ‘‘never.’’
9 In
addition, the 2010 Emergency Nurses Association study on
violence in the workplace reported that more than half of
emergency nurses had been verbally or physically threatened at
work within the preceding 7 days.
10 Agitation can also have
effects on patients as well, with case reports of death due to
untreated excited delirium.
11,12
Calming of agitated patients therefore is of primary
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the patient, medications may become necessary. One of the ﬁrst
crucial steps in prescribing medication is the establishment of a
provisional diagnosis as to its cause. It is often not possible to
make a deﬁnitive diagnosis but clinicians should attempt a
diagnosis of the most likely cause, since this can guide the
choice of medication following guidelines discussed later. The
timing of the administration of medication can be crucial to the
outcome of successfully managing an agitated patient. If an
agitated patient is medicated too aggressively or too early, it
may hinder psychiatric evaluation. If the patient is medicated
too late, it places the patient, staff, and others at increased risk
for harm. In addition, the agitation may also become more
pronounced, and greater doses or repeated medication
administration may be required to abort the agitation.
THE GOALS OF USING MEDICATION
The goal of using medication is to calm the patient so that
he or she can be more accurately assessed by clinicians.
Medication used in this manner is consistent with current
guidelines on medication administration, which state that the
proper endpoint of medication administration is calming
without inducing sleep.
7,13 In the acute setting, this more easily
permits a diagnosis of the underlying cause of the agitation and
allows patients to have some participation in their own care.
More practically, however, patients who are not asleep are
easier to discharge from the emergency department. Whether
this matters for waiting times is controversial, with recent
research indicating that the longest length of time that patients
with psychiatric illnesses spend in the emergency department
actually occurs between consultant disposition and discharge.
14
However, between emergency departments, the most variable
length of time that patients spend is between triage and
contacting of psychiatry consultants, thus potentially allowing
for improvements in these times by careful use of medication.
TYPES OF MEDICATION
There is no type of medication considered to be ‘‘best’’ in
all cases of agitation but 3 general classes of medication have
been studied and used most frequently for agitation, including
ﬁrst-generation antipsychotics, second-generation
antipsychotics, and benzodiazepines. Three routes of
administration are possible (though not for each medication):
oral/oral fast-dissolving tablets, intramuscular, or intravenous.
The workgroup believes that patients should be involved, if
possible, in both the selection of the type and the route of any
medication.
Although antipsychotics and benzodiazepines may
manage the level of agitation a patient exhibits, this does not
imply that these medications are doing so by directly
addressing the underlying etiology of the agitation. For
example, a large number of physiologic (eg, hypoxia) and
metabolic (eg, hypoglycemia) perturbations that compromise
brain function can produce delirium that is associated with
agitation. Treatment to correct the speciﬁc underlying medical
disturbance is the deﬁnitive and preferred treatment of agitation
in such cases, but this article will not attempt to address the
optimal treatments for such medical disturbances or the other
varied etiologies of agitation. Rather, this article will discuss
best-practice pharmacologic approaches to use when agitation
requires emergent management before stabilization of the
underlying etiology.
The Use of First-Generation Antipsychotics
Typical or ﬁrst-generation antipsychotics (FGA) have a
long history of use for treatment of agitation. The exact
mechanism of calming with FGAs is unknown but most likely
due to their inhibition of dopamine transmission in the human
brain, which reduces the underlying psychotic symptoms
causing the agitation. In addition, some FGAs are structurally
similar to the human inhibitory neurotransmitter gamma-
aminobutyric acid (GABA) and interact with the human GABA
receptor at high doses.
15
The phenothiazines, a class of medication that includes
low-potency antipsychotics such as chlorpromazine
(Thorazine), the ﬁrst FGA approved and marketed by the US
Food and Drug Administration (FDA), have a propensity to
cause more hypotension, more anticholinergic side effects, and
lower the seizure threshold, compared to FGAs such as
haloperidol.
16 Thus, phenothiazines are not preferred for the
treatment of acute agitation.
Haloperidol, an FGA belonging to the butyrophenone
class, is a highly potent and selective antagonist of the
dopamine-2 (D2) receptor. Haloperidol, which is FDA
approved for oral or intramuscular use in schizophrenia, has a
long track record of effective and safe use for the treatment of
agitation in the acute setting. This drug is by far the most
common FGA currently used to treat acute agitation.
3,17
Droperidol, another butyrophenone with D2 receptor–blocking
effects,hasnot beenapprovedfor psychiatric usebutisapproved
as a preanesthetic to reduce nausea and vomiting associated with
anesthesia. It has also been used widely in acute settings to treat
agitation.
Both haloperidol and droperidol have minimal effects on
vital signs, negligible anticholinergic activity, and minimal
interactions with other nonpsychiatric medications.
Unfortunately, both medications have important side effects.
Notably, droperidol and haloperidol have a propensity to
lengthen QTc intervals. Cases of torsades de pointes (TdP)
have been reported with both drugs. There is much controversy
regarding the degree and clinical signiﬁcance of this QTc
prolongation, and much research has indicated that clinically
adverse cardiac effects are rare occurrences. Nevertheless, both
drugs carry warnings about QTc prolongation in labeling of
which physicians should be aware. The haloperidol label
warning, for instance, indicates that ‘‘Higher doses and
intravenous administration of haloperidol appear to be
associated with a higher risk of QT prolongation and TdP.’’
18
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restrictive guidelines on the use of intravenous haloperidol,
typically requiring electrocardiogram (ECG) monitoring during
administration. Regardless of the true clinical risk, however, it
seems prudent for physicians to avoid intravenous
administration of haloperidol (which is not an FDA-approved
route of administration for this medication), especially for
patients who are taking other medication that can prolong QTc,
who have a preexisting long QTc, or who have other conditions
predisposing to TdP or QTc prolongation, such as underlying
cardiac abnormalities, electrolyte imbalances (particularly
hypokalemia and hypomagnesemia), or hypothyroidism. When
haloperidol must be administered intravenously, the dose
should be limited to 5 to 10 mg/day and administered in
conjunction with continuous ECG monitoring.
Droperidol carries even more stringent warnings from the
FDA about QTc prolongation and TdP. In 2007, this warning
was upgraded to a black box, the most seriouswarning the FDA
can require. This warning has subsequently proved highly
controversial, as many reviews of the FDA data have claimed
that it was based upon a very limited number of adverse events,
mostly involving doses of droperidol much higher than those
typically used to treat agitation (for an excellent review of the
data see Jackson et al
19). Other evidence also suggests that
droperidol does not warrant such strong safety concerns. For
instance, Isbister et al
20 found that doses of up to 10 mg of
droperidol had fewer adverse events than the use of midazolam
in agitated emergency department patients, and Shale et al
21 did
not ﬁnd a single case of a clinically signiﬁcant adverse cardiac
event in more than a decade of treating psychiatric emergencies
with droperidol (typically 5 mg) in a busy emergency
psychiatry unit. Emergency department–based studies, such as
by Martel and colleagues,
22 have even indicated that droperidol
may have better efﬁcacy and fewer side effects than
ziprasidone, a second-generation antipsychotic approved for
agitation. The FDA has indicated that it would revisit the
evidence for droperidol’s black-box warning either through an
internal review or through review of an external study.
19 Until
such time as the FDA warning is modiﬁed or removed,
however, it is prudent for clinicians to avoid using droperidol
for agitation, especially because it is not FDA approved for
psychiatric use.
In addition to cardiac effects, haloperidol and droperidol
carry a risk of inducing acute extrapyramidal side effects (EPS)
such as dystonia or neuroleptic malignant syndrome. High
doses of these drugs can also cause catatonic reactions due to
excessive central dopamine blockade. Although the true
incidence of such EPS events is not clear, 1 study noted that
EPS symptoms occurred in 20% of agitated patients treated
with haloperidol alone but in only 6% of agitated patients
treated with a combination of haloperidol and lorazepam.
23
This combination treatment was also found to produce more
rapid reduction in agitation. Other studies have found that
adding promethazine to haloperidol can similarly reduce the
incidence of extrapyramidal side effects.
24,25 In part because of
these studies, haloperidol is frequently administered in
combination with another medication such as lorazepam,
promethazine, or diphenhydramine.
3 However, using multiple
medications to control agitation may increase the risk both of
oversedation and interactions with other medications. In
addition, studies on patient preference have indicated that
FGAs sometimes cause dysphoria after use.
26,27 Given that
most second-generation antipsychotics have demonstrated
good efﬁcacy in treating acute agitation, have low rates of
extrapyramidal side effects (see upcoming text), and are
subjectively preferred by patients over FGAs,
26,27 the
workgroup considers haloperidol to be less preferred than
second-generation antipsychotics when an antipsychotic is
indicated.
One common clinical scenario where haloperidol may still
be the medication of choice is agitation in the context of acute
alcohol intoxication. In agitation secondary to alcohol
intoxication, medications to manage agitation should be
generally avoided if possible, with nonpharmacologic methods,
such as reduced environmental stimulation, being the preferred
method of treatment.
4,7 If medication is required, previous expert
consensus documents have recommended benzodiazepines,
given the possibility that a component of withdrawal may be
contributing to the agitation.
7 However, alcohol intoxication and
withdrawal are distinct nonoverlapping presentations, which
cliniciansaregenerallyabletodifferentiate.Inaddition,although
there is no clear scientiﬁc evidence of respiratory depression
with benzodiazepine use, there is a potential for clinically
signiﬁcant respiratory depression when benzodiazepines are
administered to alcohol-intoxicated patients, as both agents are
central nervous system (CNS) depressants.
22 As such, this
workgroup recommends the use of antipsychotics instead of
benzodiazepines to treat agitation in the context of alcohol
intoxication but the opposite in alcohol withdrawal (see
upcoming text). There are both widespread clinical experience
and published literature on the safe and effective use of
haloperidol in intoxicated patients. Second-generation
antipsychotics, however, have not been well studied in this
situation. Thus, haloperidol remains preferred by the workgroup
in this clinical scenario, although further study is needed.
THE USE OF SECOND-GENERATION
ANTIPSYCHOTICS
Atypical antipsychotics, also called second-generation
antipsychotics (SGA), were mostly developed in the 1990s and
beyond. Several of these medications are commonly used in the
acute setting. Olanzapine (Zyprexa), ziprasidone (Geodon),
and aripiprazole (Abilify) come in both intramuscular and oral
preparations. Risperidone (Risperdal) and quetiapine
(Seroquel) are available in an oral formulation only.
As a class, these medications act as antagonists at the D2
receptor, as do FGAs, but also have comparable or stronger
antagonism of other receptor subtypes, particularly serotonin-
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has actions at other receptor types, such as histamine,
norepinephrine, and a-2 receptors. Ziprasidone, for instance,
has a high afﬁnity for serotonin receptors compared to D2
receptors,
28,29 while olanzapine and quetiapine have relatively
higher afﬁnities for the histamine receptor. In general, when
compared with older drugs, SGAs have a reduced risk of near-
term side effects such as dystonia or akathisia,
30–32 with
reported rates of less than 1%.
30–32 This is lower than that
reported with haloperidol alone
23 and is some 10 times lower
than even the combination of haloperidol þ lorazepam.
23,33
With the exception of risperidone, most randomized
controlled trials of second-generation antipsychotics have been
conducted in a psychiatric emergency department or inpatient
ward, and not typical acute adult/pediatric emergency
departments. Most of this research has generally indicated that
most members of the class are effective in reducing agitation
when compared to placebo, and are at least as calming as
haloperidol.
34–40 This is true of oral and oral rapid-dissolving
formulations as well. In the limited number of studies that have
compared oral antipsychotics, the combination of oral
risperidone þlorazepam is as efﬁcacious as intramuscular
haloperidol þ lorazepam, and oral risperidone alone is as
efﬁcacious as intramuscular haloperidol alone.
37–40 Although
there are no comparisons of oral olanzapine or oral ziprasidone
with intramuscular haloperidolþlorazepam, oral olanzapine is
as efﬁcacious as oral risperidone alone.
39 With the exception of
risperidone, however, none of the SGAs have been compared
against the more common regimen of haloperidol þ
lorazepam.
37,38 Further, many of the published SGA
investigations were industry-sponsored studies.
Although there have been no head-to-head trials of SGAs
in the acute setting, published reviews have attempted to
compare the effectiveness of different drugs in the class on a
common scale, such as number-needed-to-treat.
36 These
reviews have generally indicated that most SGAs are equally
effective at reducing agitation, with 3 possible exceptions. First,
aripiprazole, the only partial D2 agonist approved for agitation,
appears slightly less efﬁcacious than other SGAs.
36 Second,
research on quetiapine has indicated that while this medication
is useful in inpatient settings, it has an unacceptably high risk of
orthostatic hypotension in the emergency department where
patients are often volume depleted.
41 Third, clozapine is only
FDA approved for treatment-resistant schizophrenia and is not
generally a ﬁrst-line agent. Thus, although more study is
needed, the use of aripiprazole, quetiapine, or clozapine cannot
be recommended as ﬁrst-line agents in the acute control of
agitation. Other agents, such as lurasidone, iloperidone, and
asenapine, are promising but have not yet been tested for acute
agitation.
Most published studies of second-generation
antipsychotics in agitated patients have not investigated their
use either with benzodiazepines or in alcohol-intoxicated
patients. Marder et al
42 described a number of adverse events in
patients who were administered the combination of olanzapine
with benzodiazepines, and this combination is not currently
recommended by the manufacturer. In 2 small retrospective
studies, Wilson and colleagues
43,44 noted that the combination
of olanzapine þ benzodiazepines did not cause vital sign
abnormalities in patients who had not ingested alcohol. In some
patients who had ingested alcohol, however, intramuscular
olanzapine þbenzodiazepines were associated with decreased
oxygen saturations. These studies were too small, however, to
provide conclusive evidence for the safety of olanzapine þ
benzodiazepines in nonintoxicated patients; thus, this
combination should be avoided. Similarly, as little research has
been conducted on other second-generation antipsychotics in
alcohol-intoxicated patients, a ﬁrst-generation antipsychotic
may be a safer choice, especially if clinicians anticipate using a
benzodiazepine as well.
A summary of dosing for medications recommended in the
treatment of agitation is provided in the Table.
BENZODIAZEPINES
Benzodiazepines such as diazepam, lorazepam, and
clonazepam act on the GABA receptor, the main inhibitory
neurotransmitter in the human brain. These medications have a
long record of efﬁcacy for agitation, and are often preferred by
clinicians when the patient is known to be suffering from
stimulant intoxication, ethanol withdrawal, or when the
etiology of agitation is undetermined. However, in agitation
involving psychosis, benzodiazepines alone may only sedate a
patient while not addressing the underlying disease that is
producing the agitation. In addition, these medications may be
oversedating and have the potential for respiratory depression
or hypotension when used parenterally in patients with
underlying respiratory conditions or in combination with other
CNS depressants such as alcohol. In a minority of patients who
chronically abuse stimulants, particularly amphetamines,
psychotic symptoms develop as a result of their amphetamine
use. In these patients, a ﬁrst- or second-generation
antipsychotic is often useful in addition to, or in place of, a
benzodiazepine.
45
SPECIFIC GUIDELINES FOR MEDICATION USE
A recommended protocol for the treatment of agitation is
shown in an algorithm in the Figure.
General Recommendations
1. The use of medication as a restraint (ie, to restrict
movement) should be discouraged. Rather, clinicians
should, to whatever extent possible, attempt a provi-
sional diagnosis of the most likely cause of the agitation
and target medication to the most likely disease.
2. Nonpharmacologic approaches, such as verbal de-
escalation and reducing environmental stimulation
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possible, before medications are administered.
3. Medication should be used to calm patients, not to
induce sleep.
4. Patients should be involved in the process of selecting
medication to whatever extent possible (eg, oral vs
intramuscular).
5. If the patient is able to cooperate with taking oral
medications, these are preferred over intramuscular
preparations.
Agitation Due to Intoxication
1. Drugs: For intoxication with most recreational drugs,
especially stimulants, benzodiazepines are generally
considered first-line agents.
47 A minority of chronic
amphetamine users develop psychotic symptoms from
their amphetamine use.
45 In these patients, a second-
generation antipsychotic may be useful in addition to a
benzodiazepine.
2. Alcohol: Medication to treat agitation associated with
alcohol intoxication should be used sparingly if at all. If
medication is required, benzodiazepines should be
avoided because of the potential to compound the risk
of respiratory depression. Thus, antipsychotics are
preferred. Haloperidol has the longest track record of
safety and efficacy and has minimal effects on
respiration. Second-generation antipsychotics, such as
olanzapine and risperidone, have not been well studied
for alcohol intoxication but may be a reasonable
alternative to haloperidol for agitation in the context of
alcohol intoxication. Of note, it is important to
distinguish agitation secondary to alcohol intoxication
versus agitation secondary to alcohol withdrawal, as
benzodiazepines are preferred over antipsychotics in
alcohol withdrawal (see the ‘‘Agitation Associated with
Delirium’’ section). Agitation in a chronic alcohol user
who exhibits features of delirium, such as tachycardia,
diaphoresis, tremors, and a low or undetectable alcohol
blood level, should be presumed to be due to
withdrawal and treated accordingly.
Agitation Due to a Psychiatric Illness
1. For psychosis-driven agitation in a patient with a
known psychiatric disorder (eg, schizophrenia, schizo-
affective disorder, bipolar disorder), antipsychotics are
preferred over benzodiazepines because they address
the underlying psychosis.
2. Second-generation antipsychotics with supportive data
for their use in acute agitation are preferred over
haloperidol either alone or with an adjunctive medica-
tion. If the patient is willing to accept oral medication,
oral risperidone has the strongest evidence for safety
Table. Medications recommended in the treatment of agitation.
Initial dose, mg Tmax* Can repeat
†
Maximum dose
(per 24 hours), mg
Oral medication
Risperidone 2 1 h 2 6
Olanzapine 5–10 6 h 2 20
Haloperidol
‡ 5 30–60 15 min 20
Lorazepam 2 20–30 2 12
Intramuscular medication
Ziprasidone 10–20 15 10 mg q 2 h,
20 mg q 4 h
40
Olanzapine 10 15–45 20 min 30
Aripiprazole 9.75 1 h 2 30
Haloperidol
‡ 5 30–60 15 min 20
Lorazepam 2 20–30 2 12
Intravenous medication
Haloperidol
§ 2–5 Immediate 4 10
§
q2h , every 2 hours; q4h , every 4 hours.
* Values are expressed as minutes unless otherwise indicated.
† Values are expressed as hours unless otherwise indicated.
‡ Likely to cause higher incidence of extrapyramidal side effects than other recommended drugs.
§ Administering haloperidol intravenously increases risk of QT prolongation. Therefore, avoid if possible, especially in patients with
borderline QT or taking other medication that can prolong QT. If given intravenously, limit dose and provide cardiac monitoring.
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supporting the use of oral antipsychotics such as
olanzapine. If the patient cannot cooperate with oral
medications, intramuscular ziprasidone or intramuscu-
lar olanzapine is preferred for acute control of agitation.
3. If an initial dose of antipsychotic is insufficient to
control agitation, the addition of a benzodiazepine
such as lorazepam is preferred to additional doses
of the same antipsychotic or to a second antipsy-
chotic.
Figure. Protocol for treatment of agitation. BZN, benzodiazepine; EPS, extrapyramidal side effects; ETOH, alcohol; IM, intramuscular.
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1. Delirium is a distinct clinical syndrome that frequently
is associated with psychosis and agitation. It is
important for clinicians to be able to recognize agitation
associated with delirium for 2 reasons. First, the
presence of delirium signals an underlying medical
perturbation affecting brain function or a rapid
change in the established environment of the brain.
This can occur with sudden withdrawal from a
chronically ingested agent (eg, alcohol or medication)
or recent ingestion of a drug or medication, such as
an anticholinergic agent in an elderly patient. Thus,
the presence of delirium should impel the treating
physician to identify the cause and correct it. Second,
the symptomatic control of agitation secondary to
delirium necessitates different choices of calming
agents than agitation from other causes.
2. Hallmarks of delirium include a decreased level of
awareness and disturbances in attention and cognition
(eg, memory) that develop over an acute time course
(hours to days). The disturbances in cognition and
awareness typically fluctuate over the course of hours
(ie, wax and wane). Prominence of visual hallucina-
tions or visual perceptual disturbances is a particularly
characteristic feature of delirium.
3. If alcohol or benzodiazepine withdrawal is the suspected
cause of delirium, then a benzodiazepine is the agent of
choice,
48 since rapid loss of chronic GABA receptor
inhibition is implicated in the delirium produced in these
circumstances. Clonidine can also be helpful in reducing
the sympathetic overdrive of alcohol or benzodiazepine
withdrawal, thereby easing delirium and agitation.
49
4. If withdrawal from another agent is suspected,
replacement of the agent with another that has similar
pharmacologic properties should be attempted if safe
and appropriate (eg, nicotine for nicotine withdrawal).
5. If the recent ingestion of a new agent (or an increased
dose of a chronically ingested agent) is the suspected
cause of the delirium, then the delirium will be self-
limiting. However, agitation may require temporary
pharmacologic management (see No. 7).
6. When an underlying medical abnormality (eg, hypo-
glycemia, electrolyte imbalance, hypoxia) is the likely
cause of delirium, the definitive treatment of the
delirium and its associated agitation is correction of the
underlying medical condition.
7. If immediate pharmacologic control of agitation is
needed in a patient with delirium that is not due to
alcohol, benzodiazepine withdrawal, or sleep depriva-
tion, second-generation antipsychotics are the preferred
agents. Haloperidol is also acceptable in low doses.
46
Benzodiazepines should be generally avoided because
they can exacerbate the delirium.
50
Agitation from Unknown or Complex (More Than 1 Cause)
Reasons
If medication is needed to control agitation in a
nondelirious patient for whom the underlying etiology of the
agitation is not clear, there is little in thewayofformal evidence
to guide the decision of which agent to use. In patients who do
not display psychosis (hallucinations, delusional thinking,
paranoia), a benzodiazepine is recommended as ﬁrst-line
treatment. An antipsychotic is recommended in patients who
are displaying psychotic features. See the Table for additional
dosing information.
CONCLUSIONS
After reviewing available evidence, the workgroup makes
the following recommendations. Best practices for treating
agitation include the following (please see speciﬁc
recommendations for detailed recommendations in different
clinical scenarios):
1. Pharmacologic treatment of agitation should be based
on an assessment of the most likely cause for the
agitation. If the agitation is from a medical condition or
delirium, clinicians should first attempt to treat this
underlying cause instead of simply medicating with
antipsychotics or benzodiazepines.
2. Oral medications should be offered over intramuscular
injections if the patient is cooperative and no medical
contraindications to their use exist.
3. Antipsychotics are indicated as first-line management
of acute agitation with psychosis of psychiatric origin.
4. When an antipsychotic is indicated for treatment of
agitation, certain SGAs (such as olanzapine, risperi-
done, or ziprasodone), with good evidence to support
their efficacy and lack of adverse events, are preferred
over haloperidol or other FGAs. Agitation secondary to
intoxication with a CNS depressant, such as alcohol,
may be an exception in which haloperidol is preferred
owing to few data on second-generation antipsychotics
in this specific clinical scenario.
5. If haloperidol is used, clinicians should consider
administering it with a benzodiazepine to reduce
extrapyramidal side effects unless contraindications to
use of this medication exist.
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